Dupilumab

Category
biologic
Half-Life (t½)
SC: 21d
Aliases
Dupixent

Pharmacological Mechanism

Fully human IgG4 mAb binding IL-4Rα subunit shared by IL-4 + IL-13 receptors → blocks both Th2 cytokines. Paradigm-shifting treatment for atopic dermatitis — moderate-severe AD failed every prior systemic, dupilumab clears ~40% and improves 70–80%. Expanded to asthma, CRSwNP, EoE, prurigo nodularis.

Half-Life & Elimination Curve (SC: 21d)

100%50%25%12.5%0%0h0×t½21d1×t½42d2×t½63d3×t½84d4×t½105d5×t½0×t½ (0h): 100% remaining (~78.4 mg/L)1×t½ (21d): 50% remaining (~39.2 mg/L)2×t½ (42d): 25% remaining (~19.6 mg/L)3×t½ (63d): 12.5% remaining (~9.8 mg/L)4×t½ (84d): 6.3% remaining (~4.9 mg/L)5×t½ (105d): 3.1% remaining (~2.45 mg/L)
Elimination (SC)
  • 0×t½0h100% (78.4 mg/L)
  • 1×t½21d50% (39.2 mg/L)
  • 2×t½42d25% (19.6 mg/L)
  • 3×t½63d12.5% (9.8 mg/L)
  • 4×t½84d6.3% (4.9 mg/L)
  • 5×t½105d3.1% (2.45 mg/L)
Elimination t½21d (SC)
Rate Constant (ke)0.00138 h⁻¹
Est. Peak (Cmax)78.4 mg/L
Clearance (CL)0.00674 L/h
97% Washout (5×t½)105d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

References